Close

UPDATE: Goldman Sachs Downgrades Intra-Cellular Therapies (ITCI) to Neutral Aug 22, 2022 05:24AM
Intra-Cellular Therapies (ITCI) Misses Q2 EPS by 16c Aug 9, 2022 07:52AM
UPDATE: Mizuho Securities Starts Intra-Cellular Therapies (ITCI) at Buy Jul 6, 2022 04:08PM
UPDATE: UBS Starts Intra-Cellular Therapies (ITCI) at Buy Jun 13, 2022 04:54PM
Intra-Cellular Therapies (ITCI) is a Bright Spot in a Dark Earnings Season, Jefferies Reiterates Buy May 11, 2022 08:39AM
View Older Stories

May 10, 2022 07:37AM Intra-Cellular Therapies (ITCI) Tops Q1 EPS by 14c
Apr 25, 2022 07:03AM Intra-Cellular Therapies (ITCI) Granted FDA Approval of New Dosage Strengths for CAPLYTA
Apr 21, 2022 08:03AM Intra-Cellular Therapies (ITCI) Appoints E. Rene Salas to its Board
Apr 13, 2022 05:47AM Needham & Company Reiterates Buy Rating, $65 Price Target on Intra-Cellular Therapies (ITCI)
Mar 29, 2022 06:24AM Needham & Company Reiterates Intra-Cellular Therapies (ITCI) at Buy with $65 PT, Sees Caplyta's Growth Accelerating & Potentially Beating Expectations
Mar 2, 2022 08:08AM Intra-Cellular Therapies (ITCI) PT Raised to $90 at Jefferies
Mar 1, 2022 03:55PM Intra-Cellular Therapies (ITCI) PT Raised to $71 at Goldman Sachs
Mar 1, 2022 08:22AM Needham & Company Reiterates Intra-Cellular Therapies (ITCI) at Buy, Anticipates Uptick Following Earnings
Mar 1, 2022 07:34AM Intra-Cellular Therapies (ITCI) Misses Q4 EPS by 5c
Feb 25, 2022 07:00AM Intra-Cellular Therapies (ITCI) PT Raised to $65 at Needham & Company
Feb 16, 2022 01:47AM Goldman Sachs Starts Intra-Cellular Therapies (ITCI) at Buy
Jan 31, 2022 02:25PM Neurocrine Biosciences (NBIX), Intra-Cellular Therapies (ITCI), and Biohaven Pharmaceutical (BHVN) Are Top Potential Acquisition Targets for Biogen (BIIB) - Mizuho Investor Survey
Jan 25, 2022 09:19AM Intra-Cellular Therapies' (ITCI) Bipolar Depression Therapy Showing Early Signs of an Acceleration - Jefferies
Jan 5, 2022 06:04AM Intra-Cellular Therapies (ITCI) Prices 9.52M Share Offering at $42/sh
Jan 4, 2022 09:24AM Pre-Open Stock Movers 01/04: (ISPC) (BLKB) (NXPI) Higher; (ITCI) (CNM) (AFCG) Lower (more...)
Jan 3, 2022 06:12PM After-Hours Stock Movers 01/03: (BLKB) (WKEY) (OWL) Higher; (ITCI) (CNM) (AFCG) Lower (more...)
Jan 3, 2022 04:01PM Intra-Cellular Therapies (ITCI) Announces Proposed Stock Offering
Dec 20, 2021 11:39AM Intra-Cellular Therapies (ITCI) PT Raised to $62 at Cantor Fitzgerald on FDA Approval
Dec 20, 2021 10:17AM Intra-Cellular Therapies (ITCI) PT Raised to $88 at Canaccord Genuity Following FDA Approval
Dec 20, 2021 08:58AM Intra-Cellular Therapies (ITCI) PT Raised to $59 at Needham & Company; Sees >$800M in Caplyta Sales by 2026
Dec 20, 2021 08:28AM Intra-Cellular Therapies (ITCI) PT Raised to $85 at Jefferies Following FDA Approval
Dec 20, 2021 06:47AM Intra-Cellular Therapies (ITCI) Announces U.S. FDA Approval of CAPLYTA for Treatment of Bipolar Depression in Adults
Dec 6, 2021 06:41AM Needham & Company Previews Intra-Cellular Therapies (ITCI) Dec. 17th PDUFA for Caplyta
Nov 9, 2021 07:37AM Intra-Cellular Therapies (ITCI) Misses Q3 EPS by 6c
Oct 21, 2021 08:42AM Intra-Cellular Therapies (ITCI) Caplyta Likely to be Approved - Jefferies
Oct 18, 2021 08:07AM Intra-Cellular Therapies (ITCI) KOL Believes Caplyta Approval Could Create an Inflection - Jefferies
Oct 18, 2021 05:18AM Intra-Cellular Therapies (ITCI) IV into FDA decision on Caplyta
Sep 27, 2021 07:30AM Intra-Cellular Therapies (ITCI) Announces Publication of Lumateperone Pivotal Phase 3 Study in Bipolar Depression in The American Journal of Psychiatry
Sep 22, 2021 04:12PM Needham & Company Starts Intra-Cellular Therapies (ITCI) at Buy
Sep 20, 2021 07:37AM Intra-Cellular Therapies (ITCI) PT Raised to $70 at Jefferies on Bullish Caplyta Survey
Aug 9, 2021 07:33AM Intra-Cellular Therapies (ITCI) Misses Q2 EPS by 5c
Jun 7, 2021 08:05AM Intra-Cellular Therapies (ITCI) Announces CAPLYTA Schizophrenia Safety and Tolerability Profile Published in the Journal, International Clinical Psychopharmacology
May 10, 2021 07:35AM Intra-Cellular Therapies (ITCI) Tops Q1 EPS by 15c, Revenues Miss
May 3, 2021 07:31AM Intra-Cellular Therapies (ITCI) Announces FDA Acceptance of CAPLYTA sNDAs for the Treatment of Bipolar Depression
Apr 19, 2021 09:05AM Intra-Cellular Therapies (ITCI) KOL Sees Good Chance of Caplyta Approval by Year End - Jefferies
Feb 25, 2021 07:47AM Intra-Cellular Therapies (ITCI) Tops Q4 EPS by 9c, Revenues Beat
Feb 22, 2021 08:09AM Intra-Cellular Therapies (ITCI) Applies for FDA Approval of CAPLYTA for the Treatment of Bipolar Depression
Jan 21, 2021 08:09AM Intra-Cellular Therapies (ITCI) Announces CAPLYTA Open-Label Safety Switching Study in Patients with Schizophrenia Published in the Journal, Schizophrenia Research
Dec 29, 2020 08:01AM Intra-Cellular Therapies (ITCI) Begins Clinical Trials for ITI-LLAI and for ITI-333
Dec 10, 2020 05:32AM UPDATE: Goldman Sachs Starts Intra-Cellular Therapies (ITCI) at Buy
Nov 9, 2020 07:36AM Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 21c, Revenues Beat
Oct 1, 2020 04:33PM Intra-Cellular Therapies (ITCI) Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer
Sep 14, 2020 05:10PM Intra-Cellular Therapies (ITCI) Director Buys 50K Shares
Sep 11, 2020 05:52AM Intra-Cellular Therapies (ITCI) Prices 11.67M Share Common Offering at $30/Sh
Sep 9, 2020 04:54PM Intra-Cellular Therapies (ITCI) PT Raised to $80 at Canaccord Genuity
Sep 9, 2020 04:01PM Intra-Cellular Therapies (ITCI) to Offer $350M in Stock
Sep 9, 2020 01:59PM Intra-Cellular Therapies (ITCI) PT Raised to $80 at BTIG
Sep 9, 2020 12:33PM Intra-Cellular Therapies (ITCI) PT Raised to $54 at JMP Securities, Following Earnings
Sep 9, 2020 09:39AM Increasing unusual put option volume: ITCI FUN
Sep 9, 2020 07:16AM Intra-Cellular Therapies (ITCI) to Resume Trading at 7:30 a.m.
View Older Stories